PITTSBURGH, Jan. 31 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received tentative approval for its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride Tablets, 500mg (base) and 1000mg (base).

Valacyclovir Hydrochloride Tablets are the generic version of GlaxoSmithKline's Valtrex^® Tablets, which had U.S. sales of approximately $1.26 billion for the same strengths in the 12-month period ending Sept. 30, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE  Mylan Laboratories Inc.
    -0-                             01/31/2007
    /CONTACT:  Patrick Fitzgerald, or Kris King, +1-724-514-1800, both of
Mylan Laboratories Inc. /
    /Web site:  http://www.mylan.com /
    (MYL)

CO:  Mylan Laboratories Inc.
ST:  Pennsylvania
IN:  HEA MTC
SU:  PDT

MG-MT
-- CLW088 --
6238 01/31/2007 07:30 EST http://www.prnewswire.com